Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

At an event called “Learning from the Past to Shape the Future: Evolution of Aortic Therapy,” Endologix recognized the surgeons who advanced aortic repair therapy and initiated early randomized controlled trials of endovascular aneurysm repair (EVAR). Prior to the early 1990s, patients who were not eligible for open surgical repair were left untreated until early innovators challenged the status quo and developed endovascular grafts.

“Randomized controlled trials are the gold standard for evaluating any therapy, and several of our honorees led studies that helped set the standard for the entire EVAR category,” said Matt Thompson, MD, Chief Medical Officer of Endologix. “These innovators revolutionized the treatment of abdominal aortic aneurysms, and we are proud to recognize the work they are doing to advance the field of vascular surgery. To advance the standard of care, we believe future products must be evaluated for superior outcomes as compared to conventional EVAR grafts.”

The distinguished honorees were:

• Jean-Pierre Becquemin, MD, study chair of the ACE trial;
• Jan Blankensteijn, MD, principal investigator of the DREAM trial;
• Roger Greenhalgh, MD, leader of the EVAR-1 trial;
• Frank Veith, MD, leader of the team that performed the first EVAR procedure in the United States in 1992, setting the course for clinical studies and therapeutic advances that would define the EVAR category.

Other physicians acknowledged for their substantial contributions included Ted Diethrich, MD, Roy Greenberg, MD, Frank Lederle, MD, Michael Marin, MD, Juan Parodi, MD, and Nikolai Volodos, MD.

About VEITH symposium

The VEITH symposium provides a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The five-day event features rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies, and new techniques. For more information, visit www.veithsymposium.org.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is in endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. For more information, visit www.endologix.com.

Cautions Regarding Forward-Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements used in this press release include Endologix’s commitment to investing in high quality evidence through randomized controlled trials and additional randomized controlled trials planned for the near future with Endologix’s next generation technologies, the accuracy of which are necessarily subject to risks and uncertainties that may cause Endologix’s actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ materially and adversely from anticipated results include, continued market acceptance, endorsement and use of Endologix’s products, the success of clinical trials relating to Endologix’s products, product research and development efforts, uncertainty in the process of obtaining and maintaining regulatory approval for Endologix’s products, Endologix’s ability to continue to access the capital markets, Endologix’s ability to protect its intellectual property rights and proprietary technologies, and other economic, business, competitive and regulatory factors. The forward-looking statements contained in this press release speak only as of the date of this press release. Endologix undertakes no obligation to update any forward- looking statements contained in this press release to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Endologix’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2017, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2018, June 30, 2018, and September 30, 2018 for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.